BetterLife Pharma, Inc. is an emerging biotechnology company, which focuses on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. The company is headquartered in Vancouver, British Columbia and currently employs 4 full-time employees. The company went IPO on 2017-12-19. The firm is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical, is a non-hallucinogenic second-generation lysergic acid diethylamide (LSD) derivative molecule that mimics the projected therapeutic potential of LSD in the treatment of disorders, such as depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical, is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound, with the potential for treatment of anxiety related disorders, including benzodiazepine dependency. The company is also refining and developing drug candidates from a set of complementary interferon-based technologies, which have the potential to engage the immune system to fight viral infections.

Industry: Pharmaceutical Preparations Peers: Lexaria Bioscience Corp